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Abstract Triple negative breast cancer (TNBC) has
caught the attention of oncologists worldwide because of
poor prognosis and paucity of targeted therapies. Gene
pathways have been widely studied, but less is known
about epigenetic factors such as microRNAs (miRNAs)
and their role in tailoring an individual systemic and sur-
gical approach for breast cancer patients. The aim of the
study was to examine selected miRNAs in TNBC core
biopsies sampled before preoperative chemotherapy and
the subsequent pathologic response in mastectomy or
breast conservation specimens. Prior to treatment, core
needle biopsies were collected from 11 female patients
with inoperable locally advanced TNBC or large resectable
tumors suitable for down-staging. In all 11 TNBC core
biopsies we analyzed 19 miRNAs per sample: 512, 190,
200, 346, 148, 449, 203, 577, 93, 126, 423, 129, 193, 182,
136, 135, 191, 122 and 222 (miRCURY LNA
TM Universal
RT microRNA polymerase chain reaction Custom Pick &
Mixpanels). The Wilcoxon signed-rank test was used to
compare related samples. Ingenuity pathway analysis was
used to evaluate potential functional signiﬁcance of dif-
ferentially expressed miRNAs. Statistical analysis showed
that 3 of 19 miRNAs differed in relation to pathologic
response i.e. good versus poor. These differences failed to
reach statistical signiﬁcance, although a trend was observed
(p = 0.06). Among these miRNAs, we identiﬁed—miR-
200b-3p, miR-190a and miR-512-5p. In summary, our
results indicate that higher miR-200b-3p, higher miR-190a
and lower miR-512-5p expression levels in core biopsies
sampled from TNBC patients may be associated with better
pathologic response to chemotherapy and the increased
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Although these results were from a small cohort, they
provide an important basis for larger, prospective, multi-
center studies to investigate the potential role of miRNAs
in neoadjuvant setting.
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Introduction
Triple negative breast cancer (TNBC) has caught the
attention of oncologists worldwide because of poor prog-
nosis and paucity of targeted therapies [1]. The preopera-
tive setting is an optimal model for in-depth research on
TNBC [2, 3]. Firstly there is the opportunity to fast-track
testing of novel biomarkers and therapeutic agents, and
secondly pathologic complete response (pCR) to neoadju-
vant systemic therapy is a valid surrogate for better out-
come in TNBC [4]. Multiple studies have demonstrated
marked sensitivity of TNBC to chemotherapy compared
with luminal A breast cancer [1–4]. Nevertheless 66–72 %
of TNBC patients fail to achieve pCR after treatment with
preoperative anthracycline and taxane-based regimens,
probably indicating adverse prognosis in terms of relapse-
free and overall survival [4]. Oncologists are therefore
pursuing more personalized therapies. Gene expression
analysis has been widely incorporated in these studies, but
less is known about epigenetic factors such as microRNAs
(miRNAs) and their role in tailoring an individual systemic
and surgical approach for breast cancer patients [5, 6].
MiRNAs are a regulatory class of small non-coding RNAs,
approximately 20–23 nucleotides in length that have been
described to post-transcriptionally modify gene expression.
The deregulation of certain miRNAs has been associated
with carcinogenesis in form of oncogenes, while others act
as tumor suppressors [7].
Aim
The aim of the study was to examine selected miRNAs in
TNBC core biopsies sampled before preoperative chemo-
therapy and the subsequent pathologic response in mas-
tectomy or breast conservation specimens.
Patients and methods
The study was conducted under Institutional Review Board
protocol # RNN/226/11/KE/13/12/2011, Medical Univer-
sity of Lodz. All patients gave written informed consent.
Prior to treatment, ultrasound-guided 14-gauge core needle
biopsies using an ultra automatic biopsy instrument (Pro-
Mag TM, Angiotech) were collected from 11 female
patients with inoperable locally advanced breast cancer or
large operable tumors suitable for down-staging, and from
three healthy controls (breast reduction procedures) at the
Cancer Center between December 2011 and April 2012.
Four to ﬁve specimens were obtained from each lesion, half
of which were frozen immediately at -80 C, for sub-
sequent miRNAs proﬁling. The other samples were paraf-
ﬁn embedded and reviewed by specialist breast
pathologists in the Department of Pathology. Estrogen
receptor (ER) and progesterone receptor (PR) status were
determined by immunohistochemistry (IHC) using the
Allred score.
Human epidermal growth factor receptor 2 (HER2)
status was evaluated by IHC or by ﬂuorescence in situ
hybridization. Samples were considered ER/PR negative
if less than 1 % of the tumor cells were immunoreactive.
Samples were considered HER2 negative with IHC 1?
staining or with a score of 2? a n dn oH E R 2g e n e
ampliﬁcation when tested by FISH. TNBC were deﬁned
as ER, PR, HER2 negative. TNM clinical staging was
assessed by mammography, ultrasound of the breast,
axilla, and abdomen, bone scan and chest X-ray. In
selected cases, MRI of the breast was performed. The
following preoperative chemotherapy regimens were
used: AT (doxorubicin 50 mg/m
2, docetaxel 75 mg/m
2)
in ﬁve patients, AC (doxorubicin 60 mg/m
2, cyclophos-
phamide 600 mg/m
2) in four patients, EC (epirubicin
75 mg/m
2, cyclophosphamide 600 mg/m
2)—in one
patient and AC?T (doxorubicin 60 mg/m
2, cyclophos-
phamide 600 mg/m
2, docetaxel 75 mg/m
2)—in one
patient. Upon completion of chemotherapy (six cycles
every 21 days, except for AC?T—eight cycles), spe-
cialist breast surgeons performed mastectomy or breast
conservation, with axillary dissection or sentinel node
biopsy. Pathologic response in the mastectomy or breast
conservation specimens was assessed by specialist breast
pathologists. pCR was deﬁned as postoperative micro-
scopic absence of invasive or in situ carcinoma in breast
tissue, and axillary lymph nodes after preoperative che-
motherapy. A near complete response with only minimal
residual disease was described as small clusters of tumor
cells in the primary tumor site or lymph node or minimal
cellularity in the surgical specimen, with 90 % loss of
tumor cells. Pathologic non-response (pNR) was deﬁned
as no change or only minor change in individual malig-
nant cells, but no reduction in overall cellularity. Partial
pathologic response (pPR) was deﬁned as reduction in
overall cellularity, not exhibiting the changes listed for
pCR, near-pCR or pNR. pCR and near-pCR were key
points in statistical analysis.
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RNA was isolated using miReasy Mini Kit 50 (Qiagen). In
all 11 TNBC core biopsies we analyzed 19 miRNAs per
sample: hsa-miR-512-5p, hsa-miR-190a, hsa-miR-200b-
3p, hsa-miR-122-5p, hsa-miR-346, hsa-miR-148b-5p, hsa-
miR-449a, hsa-miR-191-5p, hsa-miR-203a, hsa-miR-577,
hsa-miR-93-5p, hsa-miR-126-5p, hsa-miR-423-5p, hsa-
miR-129-5p, hsa-miR-193b-5p, hsa-miR-182-5p, hsa-miR-
136-5p, has-miR-222-5p and hsa-miR-135b-5p (Exiqon,
Copenhagen, Denmark). We selected these miRNAs from
the literature, miRNA database and breast cancer confer-
ences. They represent various epigenetic pathways
involved in migration, invasion, epithelial-mesenchymal
transition, cancer dormancy, switch to the fast growing
phenotype, drug resistance, etc. [8–18]. We also used
unpublished information from miRNA in vitro proﬁling
studies performed on breast cancer cell lines. For normal-
ization of the data, we have applied the average of the hsa-
miR-103a-3p and hsa-miR-107 as this was found to be the
most stable normalizer.
MiRNA real-time qPCR
10 ng RNA was reverse transcribed in 10 ll reactions
using the miRCURY LNA
TM Universal RT microRNA
PCR, Polyadenylation and cDNA synthesis kit (Exiqon).
Each RT was performed in duplicates. cDNA was diluted
100 9 and assayed in 10 ll PCR reactions according to the
protocol for miRCURY LNA
TM Universal RT microRNA
PCR; each microRNA was assayed once by qPCR on the
microRNA Ready-to-Use PCR, Custom Pick-&-Mix panel.
Negative controls excluding template from the reverse
transcription reaction were processes and proﬁled simi-
larly. Ampliﬁcation was performed in a LightCycler
 480
Real-Time PCR System (Roche, Basel, Switzerland) in
384-well plates. The ampliﬁcation curves were analyzed
using the Roche LC software, both for determination of Cp
(by the second derivative method) and for melting curve
analysis.
Data analysis
Ampliﬁcation efﬁciency was calculated using algorithms
similar to the LinReg software. All assays were inspected
for distinct melting curves and the Tm was conﬁrmed to be
within known speciﬁcations for the assay. It was important
for assays to be detected with 5 Cp’s less than the negative
control, and with Cp\37 to be included in the data ana-
lysis. Data that failed to reach these criteria were excluded
from further analysis. NormFinder was used to identify the
optimum normalizer which was the average of assays
detected in all samples (average - assay Cp).
Statistical analysis
The Wilcoxon signed-rank test was used to compare rela-
ted samples. As the study was considered preliminary and
miRNAs tested were selected due to biologic function we
did not adjust for multiple testing at this stage. Ingenuity
pathway analysis (IPA) bioinformatic database was used to
evaluate potential functional signiﬁcance of differentially
expressed miRNAs.
Results
Patients enrolled in the study were aged between 31- and
81-years-old, mean age was 54.1 years. Histopathological
tumor types were invasive ductal breast cancer (11
patients). Tumor grades were G3 in all patients. Tumor
stage was: IIB—in four patients, IIIA—in six patients, and
IIIB—in one patient. Receptor status was triple negative in
all patients. After preoperative chemotherapy, pCR was not
achieved, but near-pCR was noted in 27 % (3 out of 11)
patients (Table 1). Statistical analysis showed that 3 of 19
miRNAs differed in relation to pathologic response.
Among these miRNAs, we identiﬁed—miR-200b-3p
(p = 0.0662) up-regulated, miR-190a (p = 0.0662) up-
regulated and miR-512-5p (p = 0.0641) down-regulated.
p values of analyzed miRNAs and type of pathologic
response, e.g. near-pCR (good response) versus non-near-
pCR (poor response) are shown in Table 2 and Fig. 1. The
three miRNAs with p values close to signiﬁcance under-
went pathway analysis using the IPA software. They were
shown to be signiﬁcantly linked to cellular assembly and
organization/tissue development functional network with a
-log10(p) of nine representing a strong non-random
association (Fig. 2).
Discussion and conclusions
In the current study, we hypothesized that altered levels of
selected miRNAs correlated with sensitivity to preopera-
tive chemotherapy in TNBC patients. Numerous studies
have sought to identify miRNA markers in the serum of
cancer patients, but little is known about how miRNAs
levels found in breast cancer samples relate to drug resis-
tance [8]. Tryndyak et al. [9] have shown convincingly that
transfection of breast cancer cell line MDA-MB-231 with
miRNA-200b-3p inhibits epithelial-to-mesenchymal tran-
sition (EMT), reversing this aggressive phenotype to a
Mol Biol Rep (2014) 41:2851–2857 2853
123milder form and increasing sensitivity to doxorubicin.
Similarly, we used preoperative anthracyclines in all
patients with large tumors, and 3 out of 11, with altered
miRNA-200b-3p levels, responded well to treatment, with
a tiny 2-mm residual cluster of viable cancer cells in the
primary tumor bed, permitting breast conservation. Perhaps
in view of the small sample size, there was no statistically
signiﬁcant difference, although we observed a trend to
signiﬁcance (p = 0.06) for the hypothesized correlation.
Further research is needed and the present study should be
considered to be preliminary. Pogribny et al. [10] have
pointed out that miR-200b-3p was among the most
deregulated miRNAs in the MCF-7 cis-platin resistant
human breast adenocarcinoma cell lines. In our study none
Table 1 Clinicopathological characteristics of breast cancer patients
Patient Age
(years)
Race Histological
type
Grade Receptor
subtype
Clinical staging before
preoperative
chemotherapy
Preoperative
chemotherapy
Pathological staging
in postoperative
specimen
Type of
surgery
Pt1 31 White IDC G3 TN cT1N2 AT ypT1aN0 near-pCR BCS
Pt2 36 White IDC G3 TN cT2N2 AC?T ypT0N2 pCR in
breast, no response
in axilla
Mastectomy
Pt3 44 White IDC G3 TN cT3N1 AT ypT1aN0 near-pCR BCS
Pt4 45 White IDC G3 TN cT3N0 AC ypT2N0 Mastectomy
Pt5 47 White IDC G3 TN cT3N0 AC ypT2N0 Mastectomy
Pt6 55 White IDC G3 TN cT3N1 AT ypT1aN0 near-pCR BCS
Pt7 55 White IDC G3 TN cT2N1 AT ypT2N1 Mastectomy
Pt8 55 White IDC G3 TN cT3N0 AC ypT2N0 Mastectomy
Pt9 66 White IDC G3 TN cT4N1 AT ypT3N3 Mastectomy
Pt10 80 White IDC G3 TN cT2N2 EC ypT1cN1 Mastectomy
Pt11 81 White IDC G3 TN cT3N1 AC ypT3N0 Mastectomy
IDC invasive ductal carcinoma, TN triple negative
Preoperative chemotherapy regimens: A doxorubicin, E epirubicin, C cyclophosphamide, T docetaxel, BCS breast conserving surgery
Table 2 Association of analyzed miRNAs and type of pathologic response (good vs. poor) in TNBC
miRNA Good response average Cp SD poor response Poor response average Cp SD good response p value
hsa-miR-512-5p -11.27201 1.870254 -8.702935 0.5255918 0.064078
hsa-miR-190a -5.246738 0.9024946 -6.213683 0.8006026 0.066193
hsa-miR-200b-3p -1.997353 0.370737 -2.960642 1.2972366 0.066193
hsa-miR-346 -9.852577 1.1360037 -9.914622 0.208277 0.182422
hsa-miR-148b-5p -10.46267 0.5754232 -10.71966 0.2461868 0.220671
hsa-miR-449a -11.08681 0.6922827 -11.00305 1.1720073 0.305059
hsa-miR-203a -7.459372 1.0608366 -6.144586 2.7639684 0.379775
hsa-miR-577 -3.580436 0.3682042 -3.571102 0.4376185 0.438578
hsa-miR-93-5p -0.017407 0.9109349 -0.546595 1.6692004 0.540291
hsa-miR-126-5p -3.573845 1.4692401 -3.6294 0.3382967 0.540291
hsa-miR-423-5p -3.367891 0.6627491 -3.099422 0.1176075 0.683091
hsa-miR-129-5p -10.92072 0.9344205 -10.62819 0.84145 0.698535
hsa-miR-193b-5p -8.425986 0.6266225 -7.939713 0.5464233 0.73244
hsa-miR-182-5p -3.645599 1.0303241 -3.417605 1.793051 0.838257
hsa-miR-136-5p -4.099501 1.5175184 -4.008906 0.1797492 0.838257
hsa-miR-135b-5p -3.057166 1.638696 -3.151112 1.4110264 0.838257
hsa-miR-191-5p -2.948123 0.337603 -3.021525 0.1843927 1
hsa-miR-122-5p -12.42259 1.202344 -12.26785 0.3695887 1
hsa-miR-222-5p -11.04475 0.9186428 -10.8786 1.0133855 1
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123of the enrolled patients were treated with cis-platin, but
based on the literature such regimens are efﬁcacious in
TNBC BRCA-mutation carrier breast cancer patients.
However, in our study none of included patients were
BRCA1/2 positive. Another miRNA whose expression
differed between TNBC good and poor responders to
anthracyclines and taxanes in our analysis was miR-190a
(p = 0.0662, trend to signiﬁcance).
Almog et al. have demonstrated in human breast car-
cinoma, glioblastoma, osteosarcoma and liposarcoma that
over-expression of miRNA-190 governed the reverse
switch of fast-growing angiogenic phenotype to the dor-
mancy phase. These authors conducted their studies
mainly in human cell lines, tissue cultures, mice and
ﬁnally in 15 surgical specimens from patients with brain
tumors [11, 12]. We have analyzed miR-190a expressions
entirely in breast cancer patients, with reference to the
Fig. 1 Black bars represent patients with poor prognosis, while white
bars represent miRNA expression levels of individuals with near-pCR
(good prognosis)
Fig. 2 Functional signiﬁcance
of differentially expressed
miRNAs—miRNA-512-5p,
190a and 200b-3p (Ingenuity
pathway analysis). Diamonds
represent enzymes, triangles
represent kinases, rectangles
represent ion channels,
trapezoid markers represent
membrane transporters, inverted
trapezoids represent miRNAs,
circles represent other types of
molecules. Arrows represent
direction and type of interaction
according to Ingenuity pathway
analysis standard manual (http://
bioinfo.cnio.es/ﬁles/training/
Functional_Analysis_Course/
UBio_FuncAnalysis_Ingenuity.
pdf)
Mol Biol Rep (2014) 41:2851–2857 2855
123database of in vitro experimental models published by
other researchers.
Port et al. [13], who compared miRNAs expression
patterns (e.g., miR-512-5p) in chemoresistant cancer cell
lines, have emphasized that it would be of interest to
examine tumor samples of patients with both chemosen-
sitive and chemoresistant tumors to analyze whether the
ﬂuctuations, e.g. up- and down-regulations of selected
miRNAs, are also found in vivo.
Statistical analysis in the current in vivo study have
shown differences in miR-512-5p expression in relation to
pathologic response in TNBC patients that failed to reach
statistical signiﬁcance, although a trend was observed
(p = 0.064). Further studies in larger cohorts are needed on
account of the complexity of epigenetic modulations, their
interactions with genetic pathways and the difﬁculty of
direct translation from laboratory to clinic. We used two
bioinformatic programs TargetScan and PicTar to identify
target genes of miRNA 190a, 200b-3p and 512-5p; e.g. 104
target genes for miRNA 190a and 97 target genes for
miRNA 200b-3p were found by PicTar, 94 target genes for
miRNA 512-5p by TargetScan. Examples of target genes:
BCL11A (B cell CLL/lymphoma 11A), CALCR (calcitonin
receptor), FOXP2 (forkhead box P2), HOXC5 (homeobox
C5) for miRNA 190a; PLCB1 (phospholipase C, beta 1),
MYCN (v-myc myelocytomatosis viral related oncogene),
CCND2 (cyclin D2), RERG (RAS-like, estrogen-related
growth inhibitor) for miRNA 200b-3p; BCL2L2 (BCL2-
like 2), POLD3 polymerase (DNA-directed delta 3,
accessory subunit), c-Myc for miRNA 512-5p, etc. MiRNA
and gene network is shown in Fig. 2 [12].
A key issue of neoadjuvant trials is pCR, as a surrogate
end point, which strongly correlate with long-term survival
in TNBC [4]. In our analysis none of 11 TNBC patients
achieved pCR, but in three patients a good response to
chemotherapy (near-pCR) was noted. Symmans et al. [14]
have concluded in their study that minimal residual disease
(RCB-I, residual cancer burden I according to M.D.
Anderson criteria) in 17 % of patients carried the same
prognosis as pCR (RCB-0). Moreover, von Minckwitz
et al. have demonstrated that Ki67 measured in residual
hormone-receptor negative tumors can further subdivide
this unfavorable group of patients without a pCR. High
Ki67 levels in residual disease predict a considerable risk
of relapse, but patients with low Ki67 levels showed a
comparable outcome to patients with a pCR for disease-
free and overall survival [15]. In all three TNBC patients
who achieved near-pCR in our study very low Ki67 levels
(6 %) were measured.
In summary, our results indicate that higher miR-200b-
3p, higher miR-190a and lower miR-512-5p expression
levels in core biopsies sampled from TNBC patients may be
associated with better pathologic response to chemotherapy
and the increased feasibility of breast conserving surgery in
these patients. Although these results were from a small
cohort, they provide an important basis for larger, pro-
spective, multicenter studies to investigate the potential role
of miRNAs not only in breast cancer cells, but also in
adjacent tissues and serum as predictive biomarkers. More
precise identiﬁcation, before initiation of treatment, of those
patients who would beneﬁt from speciﬁc chemotherapeutic
regimens may improve response rates, avoid toxicity of
ineffectivetherapyandguidetheextentofnecessarysurgery
i.e. breast conservation versus mastectomy [16–18].
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